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ABSTRACT 
We report a case of a 19-year-old female with an elevated plasma B-type natriuretic peptide (BNP) level, but with-
out evidence of heart failure (HF). She presented with non-specific chest pain and a high level of the B-type na-
triuretic peptide, despite having unremarkable findings on physical examination, laboratory analysis, electrocar-
diogram, echocardiogram, chest X-ray, chest computed tomography, whole body scan, and coronary angiography. 
We attribute this finding to a genetic variation in the synthesis and cleavage of the natriuretic peptides. (Korean 
Circ J 2010;40:141-142) 
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Introduction 
 
The B-type natriuretic peptide (BNP) is synthesized 
predominantly by cardiac ventricular myocytes, the ex-
pression of which is regulated by changes in intracar-
diac pressure and/or stretch. Cardiac BNP gene expres-
sion and plasma levels generally increase in patients with 
heart failure (HF), myocardial infarction, hypertension, 
left ventricular (LV) hypertrophy, pulmonary hyperten-
sion, and renal failure.
1) However, we have managed some 
patients with elevated concentrations of the BNP and 
no evidence of HF, hypertension, or renal dysfunction. 
Thus, we report an interesting case of a young female 
patient with an elevated plasma level of the BNP. 
 
Case 
 
A 19-year-old female patient presented for evaluation 
on 7 April 2008 of non-specific chest pain of 1 month 
duration. She had no history of hypertension, diabetes, 
or renal dysfunction. The physical examination was un-
remarkable. She had worked for 6 months in a cellular 
phone factory. There were no abnormal findings on the 
electrocardiogram, echocardiogram, and treadmill test. 
The serum cardiac markers were within the normal range. 
The results of the complete blood count, blood chemis-
try, and urinalysis were within normal limits; however, 
the BNP level was 3,354.84 pg/mL. The BNP level was 
rechecked the next day, and was still elevated (3,079.29 
pg/mL). Ten days later the BNP level was 2,982.31 pg/ 
mL. On 30 June 2008 she was admitted to our hospital 
due to atypical chest pain. The physical examination was 
unremarkable. There were no abnormal findings on the 
chest X-ray, chest computed tomography, whole body 
scan, and coronary angiography with a spasm stress test. 
There were no regional wall motion abnormalities on 
the left ventriculogram and LV end-diastolic pressure 
was 10 mmHg. The laboratory findings, including a com-
plete blood count, blood chemistries, a pregnancy test, 
the antinuclear antibody titer, a peripheral blood smear, 
and a urine test were all normal, except for a high pla-
sma level of BNP (3,437.80 pg/mL).  
Pulmonary function testing showed that spirometry 
was within normal limits. She was discharged on diltia-
zem and a diuretic and was symptom-free. During the 
follow-up, the BNP level was measured twice as an out-
patient and was persistently elevated (2,904.1 pg/mL 
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and 4,000 pg/mL) (Fig. 1). 
 
Discussion 
 
The BNP is synthesized and secreted primarily from 
LV cardiomyocytes in response to increasing wall stress, 
particularly during diastole.
2) Cleavage of the precursor 
peptide (proBNP) produces BNP and the correspond-
ing amino-terminal component (NT-proBNP), which 
are secreted in a 1 : 1 ratio and can be detected in the pe-
ripheral circulation.
3) The plasma levels of these peptides 
correlate strongly with each other. The BNP is bioactive 
and has a shorter half-life as a result of clearance by 
neutral endopeptidase and natriuretic peptide C-type 
receptors. Thus, levels are lower than for the more st-
able NT-proBNP.
4) The levels of both peptides increase 
with LV pressure or volume loading, and reflect the se-
verity of LV dysfunction. In addition, the levels of both 
peptides correlate inversely with LV ejection fraction 
and positively with increasing LV mass and indices of 
LV filling pressure.
5) There is wide inter-individual va-
riation in BNP and NT-proBNP levels. Up to 80% of 
inter-individual variation in peptide levels is explained 
by LV and diastolic functions, right ventricular dysfunc-
tion, renal function, age, and mitral regurgitation.
6) Al-
though Baggish et al.
7) previously reported the possible 
causes of NT-proBNP elevation unrelated to HF, such 
as heart muscle disease, valvular heart disease, atrial ar-
rhythmias, anemia, critical illnesses, ischemic stroke, and 
pulmonary heart disease syndromes, the patient pre-
sented herein had none of the these causes. Hereditary 
factors may be responsible for a significant proportion 
of residual variation in BNP levels.
8) In this interesting 
case, the patient has no remarkable findings to account 
for the high levels of the BNP. We therefore suggest that 
hereditary factors may be responsible for a significant 
proportion of residual variation in BNP levels and fur-
ther studies are required to describe the basis and need 
for treatment (if any) of elevated BNP levels in such pa-
tients.  
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The plasma BNP level according to each check time
 1  2  3  4  5  6 
Check  date 2008-4-7 2008-4-8 2008-4-17 2008-7-3 2008-7-10 2008-10-16
BNP level 
(pg/mL) 
3354.84 3079.29  2982.31  3437.8  2904.9  4000 
Fig. 1. The B-type natriuretic peptide (BNP) levels were check-
ed six times during the previous clinical follow-up. The 3rd and
5th BNP measurements had a lower level, which may reflect con-
tinuous medications with diltiazem and a diuretic. The 4th and 6th 
BNP measurements were elevated and may reflect non-compli-
ance with therapy. 